Información del curso
Descripción
Provider | American Society of Hematology (ASH) |
Accreditation Type | ·Physicians—maximum of 1.50 AMA PRA Category 1 Credit(s)™ and 1.50 ABIM MOC points |
Accreditor | American Society of Hematology |
Release Date | 10/2022 |
Expiration Date | 10/2023 |
Estimated Time to Complete Activity | 90 minutes |
Description
This case-based module will introduce CAR T-cell therapy and review patient cases in MM, B-ALL, and BCL/DLBCL. This activity will help you identify appropriate patients for CAR T-cell therapy and cover the toxicities associated with this treatment.
Target Audience
This educational activity is intended for hematologists, oncologists, and other healthcare team members involved in the treatment of patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and B-cell lymphoma/diffuse large B-cell lymphoma.Learning Objectives
Upon completion of this course, the learners should be able to:
- Summarize key aspects of approved or emerging CAR T-cell therapies for use in MM, B-ALL, and BCL/DLBCL, including development, mechanism, specific indications, and serious adverse events
- Select patients who might be appropriate for CAR T-cell therapy
- Complete timely and informative referrals to CAR T-cell therapy specialty centers
- Create a plan that reflects issues to be monitored and addressed post-CAR T-cell therapy in the short- and long-term
Secciones
General
0 activities
Overview
0 activities
Disclosures for Learners
1 activities
Content
1 activities
Evaluation
2 activities
Certificates
1 activities
Credits
4 activities
Method of Participation/How to Receive Credit
0 activities
Accredited Provider
0 activities
Physician Credit Designation
0 activities
1
1
2
1
3
1